Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

Related Articles by Review for PubMed (Select 19958227)

1.

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.

Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, Ma Z, Graham S, Chaubal M, Werling J, Rabinow B, Dou H, Gendelman HE.

Nanomedicine (Lond). 2009 Dec;4(8):903-17. doi: 10.2217/nnm.09.71.

2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.

Wilkins E.

J HIV Ther. 2008 Mar;13(1):9-18. Review. No abstract available.

PMID:
18953268
4.
5.

Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings.

Cressey TR, Plipat N, Fregonese F, Chokephaibulkit K.

Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):347-61. Review.

PMID:
17539743
6.

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.

Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH.

Pharm World Sci. 1997 Aug;19(4):159-75. Review.

PMID:
9297727
7.

The choice of HIV protease inhibitor: indinavir is currently the best option.

[No authors listed]

Prescrire Int. 1999 Apr;8(40):55-60. Review.

PMID:
10848067
8.

Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement.

Rathbun RC, Rossi DR.

Ann Pharmacother. 2002 Apr;36(4):702-6. Review.

PMID:
11918523
9.

NanoART, neuroAIDS and CNS drug delivery.

Nowacek A, Gendelman HE.

Nanomedicine (Lond). 2009 Jul;4(5):557-74. doi: 10.2217/nnm.09.38. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk